Chemomab Therapeutics (CMMB) Competitors $1.07 -0.06 (-5.31%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 04/3/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. IGMS, ALGS, ADAP, ENTX, IMAB, EPIX, ALTS, SKYE, ZIVO, and SCLXShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include IGM Biosciences (IGMS), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Entera Bio (ENTX), I-Mab (IMAB), ESSA Pharma (EPIX), Janone (ALTS), Skye Bioscience (SKYE), ZIVO Bioscience (ZIVO), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. IGM Biosciences Aligos Therapeutics Adaptimmune Therapeutics Entera Bio I-Mab ESSA Pharma Janone Skye Bioscience ZIVO Bioscience Scilex Chemomab Therapeutics (NASDAQ:CMMB) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Does the media favor CMMB or IGMS? In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 2 articles in the media. IGM Biosciences' average media sentiment score of 0.92 beat Chemomab Therapeutics' score of 0.53 indicating that IGM Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IGM Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CMMB or IGMS? IGM Biosciences received 53 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 65.52% of users gave Chemomab Therapeutics an outperform vote while only 47.68% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1965.52% Underperform Votes1034.48% IGM BiosciencesOutperform Votes7247.68% Underperform Votes7952.32% Is CMMB or IGMS more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,534.03%. Chemomab Therapeutics' return on equity of -101.70% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% IGM Biosciences -7,534.03%-155.42%-61.04% Do insiders and institutionals hold more shares of CMMB or IGMS? 46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, CMMB or IGMS? Chemomab Therapeutics has higher earnings, but lower revenue than IGM Biosciences. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$0.90-1.19IGM Biosciences$2.68M25.88-$246.42M-$3.24-0.36 Which has more volatility and risk, CMMB or IGMS? Chemomab Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Do analysts recommend CMMB or IGMS? Chemomab Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 741.12%. IGM Biosciences has a consensus target price of $5.50, suggesting a potential upside of 374.14%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90 SummaryChemomab Therapeutics beats IGM Biosciences on 10 of the 16 factors compared between the two stocks. Remove Ads Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.36M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-1.076.9923.2518.07Price / SalesN/A198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book0.695.926.493.99Net Income-$24.22M$142.37M$3.21B$247.18M7 Day Performance-2.73%-9.32%-6.42%-6.42%1 Month Performance-29.14%-10.26%-0.68%-7.44%1 Year Performance32.59%-15.08%6.05%-4.31% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.3503 of 5 stars$1.07-5.3%$9.00+741.1%+32.6%$15.36MN/A-1.0720Gap DownIGMSIGM Biosciences4.7258 of 5 stars$1.26+5.9%$5.50+336.5%-87.2%$71.13M$2.68M-0.35190Gap DownALGSAligos Therapeutics3.8819 of 5 stars$11.63+8.2%$70.00+501.9%-74.3%$71.11M$3.95M-0.8790Gap DownADAPAdaptimmune Therapeutics2.6128 of 5 stars$0.28-4.8%$2.18+687.6%-76.5%$70.83M$175.04M-1.26490Analyst ForecastGap DownENTXEntera Bio2.5608 of 5 stars$1.95flat$10.00+412.8%-5.2%$69.78M$99,000.00-7.5020Earnings ReportShort Interest ↓IMABI-Mab1.962 of 5 stars$0.87+2.0%$7.00+706.6%-60.1%$69.33M$3.27M0.00380News CoverageGap DownEPIXESSA Pharma2.808 of 5 stars$1.56-1.3%$9.50+509.0%-80.3%$69.25MN/A-2.2650ALTSJanoneN/A$4.91+3.8%N/AN/A$69.08M$7.11M0.00170Short Interest ↓Gap DownSKYESkye Bioscience1.1836 of 5 stars$2.35-13.9%$18.00+666.0%-89.5%$68.26MN/A-3.2311Gap UpZIVOZIVO BioscienceN/A$18.00+1.1%N/A+110.0%$67.30M$15,850.00-3.6910Gap DownSCLXScilex2.0943 of 5 stars$0.28-1.5%$14.00+4,972.5%-81.5%$67.15M$55.15M-0.3380Analyst ForecastNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies IGMS Competitors ALGS Competitors ADAP Competitors ENTX Competitors IMAB Competitors EPIX Competitors ALTS Competitors SKYE Competitors ZIVO Competitors SCLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
